PW PeptideWars Evidence league

Growth hormone secretagogues

CJC-1295

An investigational long-acting GHRH analog studied for growth hormone and IGF-1 signaling.

DAC:GRFLong-acting GHRH analog

Concise answer

What is CJC-1295?

CJC-1295 is an investigational GHRH analog that can affect GH and IGF-1 markers in human research. It is not FDA-approved for consumer anti-aging or body-composition use.

Definition

What It Is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone designed to prolong signaling compared with native GHRH.

Status

Legal and Regulatory Notes

  • FDA: Not FDA-approved as a marketed medication.
  • Research: Small human studies show biomarker effects, but that is not the same as proven clinical benefit.
  • Sport: Growth hormone releasing factors and related analogs are prohibited in sport under WADA categories.

Research map

How CJC-1295 Is Being Studied

Growth hormone and IGF-1 biomarker responseProteomic changes related to the GH/IGF-1 axisAnti-doping detection and growth hormone secretagogue classificationPotential risks of sustained GH-axis manipulation

People

Human Research

Human research includes small controlled studies in healthy adults measuring GH/IGF-1-related biomarkers. These studies do not establish anti-aging or recovery outcomes.

Models

Animal and Cell Research

Animal and mechanistic studies can support biologic plausibility, but human safety and clinical outcomes remain the critical gap.

Safety

Known Risks and Side Effects

  • Potential GH/IGF-1 axis adverse effects such as fluid retention or glucose-related issues
  • Unknown long-term safety outside controlled research
  • Anti-doping violations for tested athletes
  • Product quality and identity issues outside regulated drug channels

Compliance

Interpretation Guardrails

  • GH-axis manipulation should not be treated as wellness optimization without clinician oversight.
  • No dosing, cycling, or stacking information is provided.
  • Talk to an endocrinologist or licensed clinician for hormone-related questions.

Internal links

Related Battles and Profiles

Battle CJC-1295 vs Ipamorelin Two GH-axis research peptides compared by mechanism, evidence, risk, and anti-doping status. Profile Ipamorelin A selective growth hormone secretagogue studied in early human pharmacology and gastrointestinal motility contexts. Profile Sermorelin A GHRH analog historically studied for growth hormone deficiency testing and pediatric growth contexts. Profile Tesamorelin An FDA-approved GHRH analog product for a specific HIV-associated lipodystrophy indication. Guide Growth Hormone Secretagogues CJC-1295, ipamorelin, sermorelin, and tesamorelin compared by mechanism, evidence, and regulatory status. Guide Research-Only Peptides How to spot compounds where marketing has outrun human evidence and regulatory approval.
FAQ

Common Questions

Is CJC-1295 FDA-approved?

No. PeptideWars classifies CJC-1295 as investigational and not FDA-approved.

Does CJC-1295 increase growth hormone?

Small human studies show GH/IGF-1 biomarker effects, but biomarker movement is not the same as proven clinical benefit.

Is CJC-1295 banned in sport?

Growth hormone releasing factors and secretagogues are high-risk under anti-doping rules. Tested athletes should consult official sport rules.

Sources

Citations and Official References

  1. Activation of the GH/IGF-1 Axis by CJC-1295, a Long Acting GHRH Analog PMC
  2. The Prohibited List WADA

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.